Literature DB >> 26253645

Linezolid underexposure in a patient co-treated with venlafaxine.

Piergiorgio Cojutti1,2, Massimo Crapis3, Matteo Bassetti3, William Hope4, Federico Pea5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26253645     DOI： 10.1007/s00228-015-1922-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  10 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Linezolid and rifampin: Drug interaction contrary to expectations?

Authors:  Hannes Egle; Rainer Trittler; Klaus Kümmerer; Sebastian W Lemmen
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

3.  Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient.

Authors:  Federico Pea; Luigia Scudeller; Manuela Lugano; Umberto Baccarani; Federica Pavan; Marcello Tavio; Mario Furlanut; Giorgio Della Rocca; Fabrizio Bresadola; Pierluigi Viale
Journal:  Clin Infect Dis       Date:  2006-02-01       Impact factor: 9.079

4.  Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: a case report.

Authors:  Federico Pea; Barbara Cadeo; Pier G Cojutti; Davide Pecori; Matteo Bassetti
Journal:  Ther Drug Monit       Date:  2014-10       Impact factor: 3.681

5.  Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.

Authors:  Corbin J Bachmeier; David Beaulieu-Abdelahad; Nowell J Ganey; Michael J Mullan; Gary M Levin
Journal:  Biopharm Drug Dispos       Date:  2011-03-28       Impact factor: 1.627

6.  Venlafaxine induces P-glycoprotein in human Caco-2 cells.

Authors:  M J Ehret; G M Levin; M Narasimhan; A Rathinavelu
Journal:  Hum Psychopharmacol       Date:  2007-01       Impact factor: 1.672

7.  Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.

Authors:  Federico Pea; Pierluigi Viale; Piergiorgio Cojutti; Barbara Del Pin; Eleonora Zamparini; Mario Furlanut
Journal:  J Antimicrob Chemother       Date:  2012-05-02       Impact factor: 5.790

Review 8.  Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial.

Authors:  Dennis J Stalker; Gail L Jungbluth
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.

Authors:  G M Levin; L A Nelson; C L DeVane; S L Preston; G Eisele; S W Carson
Journal:  Psychopharmacol Bull       Date:  2001

10.  Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study.

Authors:  Michael Zoller; Barbara Maier; Cyrill Hornuss; Christina Neugebauer; Gundula Döbbeler; Dorothea Nagel; Lesca Miriam Holdt; Mathias Bruegel; Thomas Weig; Béatrice Grabein; Lorenz Frey; Daniel Teupser; Michael Vogeser; Johannes Zander
Journal:  Crit Care       Date:  2014-07-10       Impact factor: 9.097
  10 in total
  3 in total

1.  Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.

Authors:  Piergiorgio Cojutti; Manjunath P Pai; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

Review 2.  A Review of Population Pharmacokinetic Analyses of Linezolid.

Authors:  Enrique Bandín-Vilar; Laura García-Quintanilla; Ana Castro-Balado; Irene Zarra-Ferro; Miguel González-Barcia; Manuel Campos-Toimil; Víctor Mangas-Sanjuan; Cristina Mondelo-García; Anxo Fernández-Ferreiro
Journal:  Clin Pharmacokinet       Date:  2022-06-14       Impact factor: 5.577

3.  Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?-Experience from a prospective observational study.

Authors:  Jie Fang; Congqin Chen; Yan Wu; Min Zhang; Ying Zhang; Guochao Shi; Yijin Yao; Hong Chen; Xiaolan Bian
Journal:  Ann Transl Med       Date:  2020-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.